Skip to main
ALZN
ALZN logo

Alzamend Neuro (ALZN) Stock Forecast & Price Target

Alzamend Neuro (ALZN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alzamend Neuro Inc is positioned favorably in the biopharmaceutical sector, focusing on innovative treatments for neurodegenerative diseases and psychiatric disorders, particularly Alzheimer's. The company reported positive top-line results in June 2023, indicating promising progress in its clinical development pipeline, which includes unique therapeutic candidates, AL001 and AL002. Additionally, the current valuation of Alzamend Neuro appears attractive, suggesting potential for significant upside as the company continues to achieve key milestones and generates positive data.

Bears say

Alzamend Neuro Inc reported a net loss of $2.7 million, translating to an earnings per share (EPS) of $(1.28), which significantly surpassed earlier estimates of $(0.69). The company, operating in the early clinical stages of biopharmaceutical development, is heavily reliant on the success of its two drug candidates aimed at treating neurodegenerative diseases, notably Alzheimer's, which poses inherent risks linked to clinical trial outcomes and regulatory approvals. Additionally, the financial outlook is compounded by balance sheet and liquidity risks, competition, and broader macroeconomic factors, raising concerns about the company's ability to achieve commercialization and secure appropriate reimbursement for its products.

Alzamend Neuro (ALZN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alzamend Neuro (ALZN) Forecast

Analysts have given Alzamend Neuro (ALZN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Alzamend Neuro (ALZN) has a Strong Buy consensus rating as of Nov 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alzamend Neuro (ALZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.